Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

2026-03-28 - 22:13

TAIPEI, March 28, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic